BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen Y, Wang X, Deng X, Zhang Y, Liao R, Li Y, Yang H, Chen K. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma. Front Immunol 2021;12:676922. [PMID: 34335575 DOI: 10.3389/fimmu.2021.676922] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou J, Guo T, Zhou L, Bao M, Wang L, Zhou W, Tan S, Li G, He B, Guo Z. The ferroptosis signature predicts the prognosis and immune microenvironment of nasopharyngeal carcinoma. Sci Rep 2023;13:1861. [PMID: 36732567 DOI: 10.1038/s41598-023-28897-2] [Reference Citation Analysis]
2 Wang L, Wang L, He P. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma. Front Genet 2022;13:1064432. [PMID: 36568383 DOI: 10.3389/fgene.2022.1064432] [Reference Citation Analysis]
3 Zhang X, Wen J, Zhang G, Fan W, Tan J, Liu H, Li J. Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma. Transl Oncol 2022;27:101600. [PMID: 36481605 DOI: 10.1016/j.tranon.2022.101600] [Reference Citation Analysis]
4 Li L, Zou B, Zhao J, Liang J, She Z, Zhou W, Lin S, Tian L, Luo W, He F. A novel DNA damage repair-related signature for predicting prognositc and treatment response in non-small lung cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.961274] [Reference Citation Analysis]
5 Testa U, Pelosi E, Castelli G. Clinical value of identifying genes that inhibit hepatocellular carcinomas. Expert Rev Mol Diagn 2022;22:1009-35. [PMID: 36459631 DOI: 10.1080/14737159.2022.2154658] [Reference Citation Analysis]
6 Shi C, Qin K, Lin A, Jiang A, Cheng Q, Liu Z, Zhang J, Luo P. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. J Exp Clin Cancer Res 2022;41:268. [DOI: 10.1186/s13046-022-02469-0] [Reference Citation Analysis]
7 Smith MA, Van Alsten SC, Walens A, Damrauer JS, Maduekwe UN, Broaddus RR, Love MI, Troester MA, Hoadley KA. DNA Damage Repair Classifier Defines Distinct Groups in Hepatocellular Carcinoma. Cancers 2022;14:4282. [DOI: 10.3390/cancers14174282] [Reference Citation Analysis]
8 Lou S, Wang Y, Zhang J, Yin X, Zhang Y, Wang Y, Xue Y. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer. Front Immunol 2021;12:806324. [PMID: 35082793 DOI: 10.3389/fimmu.2021.806324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Xia W, Peng T, Guan R, Zhou Y, Zeng C, Lin Y, Wu Z, Tan H. Development of a novel prognostic nomogram for the early recurrence of liver cancer after curative hepatectomy. Ann Transl Med 2021;9:1541. [PMID: 34790747 DOI: 10.21037/atm-21-4837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]